These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 32239677)
21. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298 [TBL] [Abstract][Full Text] [Related]
22. Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically Resected Thalamic Gliomas in Children. Chiba K; Aihara Y; Masui K; Abe K; Komori T; Kawamata T World Neurosurg; 2020 Feb; 134():e530-e539. PubMed ID: 31704359 [TBL] [Abstract][Full Text] [Related]
23. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma. Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726 [TBL] [Abstract][Full Text] [Related]
24. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473 [TBL] [Abstract][Full Text] [Related]
25. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993 [TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D; Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687 [TBL] [Abstract][Full Text] [Related]
27. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma. Youland RS; Kreofsky CR; Schomas DA; Brown PD; Buckner JC; Laack NN J Neurooncol; 2017 Dec; 135(3):535-543. PubMed ID: 28836106 [TBL] [Abstract][Full Text] [Related]
28. Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Mirow C; Pietsch T; Berkefeld S; Kwiecien R; Warmuth-Metz M; Falkenstein F; Diehl B; von Hornstein S; Gnekow AK Pediatr Blood Cancer; 2014 Mar; 61(3):457-63. PubMed ID: 24039013 [TBL] [Abstract][Full Text] [Related]
29. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904 [TBL] [Abstract][Full Text] [Related]
30. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603 [TBL] [Abstract][Full Text] [Related]
31. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222 [TBL] [Abstract][Full Text] [Related]
32. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis. Kai Z; Dingyang L; Zhuanyi Y World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486 [TBL] [Abstract][Full Text] [Related]
33. Benign Glioma. Wu PB; Filley AC; Miller ML; Bruce JN Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934 [TBL] [Abstract][Full Text] [Related]
34. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations. Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135 [TBL] [Abstract][Full Text] [Related]
35. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294 [TBL] [Abstract][Full Text] [Related]
36. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project. Pala A; Nadji-Ohl M; Faust K; Rückriegel S; Roder C; von der Brelie C; Forster MT; Löbel F; Schommer S; Löhr M; Renovanz M; Grübel N; Rothenbacher D; König R; Engelke J; Schmitz B; Wirtz CR; Ringel F; Senft C; Rohde V; Tatagiba M; Ernestus RI; Vajkoczy P; Ganslandt O; Nagel G; Coburger J J Neurol Surg A Cent Eur Neurosurg; 2020 Jan; 81(1):48-57. PubMed ID: 31550737 [TBL] [Abstract][Full Text] [Related]
37. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362 [TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of centrally located low-grade glioma in children. Terashima K; Chow K; Jones J; Ahern C; Jo E; Ellezam B; Paulino AC; Okcu MF; Su J; Adesina A; Mahajan A; Dauser R; Whitehead W; Lau C; Chintagumpala M Cancer; 2013 Jul; 119(14):2630-8. PubMed ID: 23625612 [TBL] [Abstract][Full Text] [Related]
39. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact. Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238 [TBL] [Abstract][Full Text] [Related]
40. In vitro neurosphere formation correlates with poor survival in glioma. C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]